P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study.
A. Stopeck(National Cancer Center), Ada Braun(National Cancer Centre Japan), Denise A. Yardley(Sarah Cannon), Alexander Paterson, Toshimi Takano(The Cancer Institute Hospital), Yasuhiro Fujiwara(Yokohama City University), Boer RH de(National Cancer Center), Miguel Martín(Hospital General Universitario Gregorio Marañón), Philippe Solal‐Céligny(Institut de Cancérologie de l'Ouest), J.J. Body(Université Libre de Bruxelles), G.G. Steger(National Cancer Center), Allan Lipton(National Cancer Centre Japan), Katia Tonkin(National Cancer Centre Japan), Michelle Fan(National Cancer Centre Japan), Jacek Jassem(Gdańsk Medical University)
Cited by 15
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k